125 related articles for article (PubMed ID: 33265966)
1. Study of Chemotherapy-Induced Cognitive Impairment in Women with Breast Cancer.
Rodríguez Martín B; Fernández Rodríguez EJ; Rihuete Galve MI; Cruz Hernández JJ
Int J Environ Res Public Health; 2020 Nov; 17(23):. PubMed ID: 33265966
[TBL] [Abstract][Full Text] [Related]
2. Chemotherapy-induced cognitive impairment in breast cancer survivors: A systematic review of studies from 2000 to 2021.
Amani O; Mazaheri MA; Moghani MM; Zarani F; Choolabi RH
Cancer Rep (Hoboken); 2024 Feb; 7(2):e1989. PubMed ID: 38351543
[TBL] [Abstract][Full Text] [Related]
3. Cancer-related cognitive impairment and wellbeing in patients with newly diagnosed aggressive lymphoma compared to population norms and healthy controls: an exploratory study.
Gates P; Dhillon HM; Krishnasamy M; Wilson C; Gough K
Support Care Cancer; 2024 Mar; 32(4):238. PubMed ID: 38512692
[TBL] [Abstract][Full Text] [Related]
4. Relationships between cytokines and cognitive function from pre- to post-chemotherapy in patients with breast cancer.
Janelsins MC; Lei L; Netherby-Winslow C; Kleckner AS; Kerns S; Gilmore N; Belcher E; Thompson BD; Werner ZA; Hopkins JO; Long J; Cole S; Culakova E
J Neuroimmunol; 2022 Jan; 362():577769. PubMed ID: 34871864
[TBL] [Abstract][Full Text] [Related]
5. Neurophysiologic and ophthalmic markers of chemotherapy-related cognitive impairment in patients diagnosed with hematologic cancer: A feasibility study.
Anderson DE; Kedar S; Bhatt VR; Schmid K; Holstein SA; Rizzo M
J Neurol Sci; 2020 Mar; 410():116644. PubMed ID: 31901718
[TBL] [Abstract][Full Text] [Related]
6. Cognitive impairments associated with chemotherapy in women with breast cancer: a meta-analysis and meta-regression.
Oliveira MEC; Torres GSV; Franklin RG; Gomes KAL; Nóbrega WFS; Fernandes TP; Santos NA
Braz J Med Biol Res; 2023; 56():e12947. PubMed ID: 37851791
[TBL] [Abstract][Full Text] [Related]
7. Changes in Subjective Measures of Cognitive Function in Older Adults From the Initiation Through 12 Months After the Receipt of Chemotherapy.
Utne I; Stokke K; Ritchie C; Løyland B; Grov EK; Rasmussen HL; Lindemann K; Paul SM; Torstveit AH; Miaskowski C
Cancer Nurs; 2023 Nov-Dec 01; 46(6):E365-E374. PubMed ID: 35781267
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapy-related cognitive impairment: What we need to know and what we can do.
Miyashita M
Asia Pac J Oncol Nurs; 2024 Jan; 11(1):100334. PubMed ID: 38098856
[No Abstract] [Full Text] [Related]
9. Prevalence of cognitive impairment and change in patients with breast cancer: A systematic review of longitudinal studies.
Dijkshoorn ABC; van Stralen HE; Sloots M; Schagen SB; Visser-Meily JMA; Schepers VPM
Psychooncology; 2021 May; 30(5):635-648. PubMed ID: 33533166
[TBL] [Abstract][Full Text] [Related]
10. Cancer Chemotherapy Related Cognitive Impairment and the Impact of the Alzheimer's Disease Risk Factor
Fernandez HR; Varma A; Flowers SA; Rebeck GW
Cancers (Basel); 2020 Dec; 12(12):. PubMed ID: 33352780
[TBL] [Abstract][Full Text] [Related]
11. Telomere lengths in women treated for breast cancer show associations with chemotherapy, pain symptoms, and cognitive domain measures: a longitudinal study.
Alhareeri AA; Archer KJ; Fu H; Lyon DE; Elswick RK; Kelly DL; Starkweather AR; Elmore LW; Bokhari YA; Jackson-Cook CK
Breast Cancer Res; 2020 Dec; 22(1):137. PubMed ID: 33276807
[TBL] [Abstract][Full Text] [Related]
12. Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study.
Tan AR; Im SA; Mattar A; Colomer R; Stroyakovskii D; Nowecki Z; De Laurentiis M; Pierga JY; Jung KH; Schem C; Hogea A; Badovinac Crnjevic T; Heeson S; Shivhare M; Kirschbrown WP; Restuccia E; Jackisch C;
Lancet Oncol; 2021 Jan; 22(1):85-97. PubMed ID: 33357420
[TBL] [Abstract][Full Text] [Related]
13. Understanding Patterns of Brain Metastasis in Triple-Negative Breast Cancer and Exploring Potential Therapeutic Targets.
Lv Y; Ma X; Du Y; Feng J
Onco Targets Ther; 2021; 14():589-607. PubMed ID: 33519208
[TBL] [Abstract][Full Text] [Related]
14. Designing deep learning studies in cancer diagnostics.
Kleppe A; Skrede OJ; De Raedt S; Liestøl K; Kerr DJ; Danielsen HE
Nat Rev Cancer; 2021 Mar; 21(3):199-211. PubMed ID: 33514930
[TBL] [Abstract][Full Text] [Related]
15. Berberine ameliorates doxorubicin-induced cognitive impairment (chemobrain) in rats.
Shaker FH; El-Derany MO; Wahdan SA; El-Demerdash E; El-Mesallamy HO
Life Sci; 2021 Mar; 269():119078. PubMed ID: 33460662
[TBL] [Abstract][Full Text] [Related]
16. Subjective cognition and mood in persistent chemotherapy-related cognitive impairment.
Vega JN; Albert KM; Mayer IA; Taylor WD; Newhouse PA
J Cancer Surviv; 2022 Jun; 16(3):614-623. PubMed ID: 33973154
[TBL] [Abstract][Full Text] [Related]
17. Cognitive Effects and Depression Associated With Taxane-Based Chemotherapy in Breast Cancer Survivors: A Meta-Analysis.
Ibrahim EY; Domenicano I; Nyhan K; Elfil M; Mougalian SS; Cartmel B; Ehrlich BE
Front Oncol; 2021; 11():642382. PubMed ID: 33996556
[No Abstract] [Full Text] [Related]
18. A narrative review of risk factors and interventions for cancer-related cognitive impairment.
Bai L; Yu E
Ann Transl Med; 2021 Jan; 9(1):72. PubMed ID: 33553365
[TBL] [Abstract][Full Text] [Related]
19. Neurocognitive Effects of Chemotherapy for Colorectal Cancer: A Systematic Review and a Meta-Analysis of 11 Studies.
Hwang SY; Kim K; Ha B; Lee D; Kim S; Ryu S; Yang J; Jung SJ
Cancer Res Treat; 2021 Oct; 53(4):1134-1147. PubMed ID: 33735557
[TBL] [Abstract][Full Text] [Related]
20. Chemobrain in Breast Cancer: Mechanisms, Clinical Manifestations, and Potential Interventions.
Onzi GR; D'Agustini N; Garcia SC; Guterres SS; Pohlmann PR; Rosa DD; Pohlmann AR
Drug Saf; 2022 Jun; 45(6):601-621. PubMed ID: 35606623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
